Sean David to Dopamine Uptake Inhibitors
This is a "connection" page, showing publications Sean David has written about Dopamine Uptake Inhibitors.
Connection Strength
1.760
-
Commentary on Chen et?al. (2014): another step on the road to clinical utility of pharmacogenetics for smoking cessation? Addiction. 2014 Jan; 109(1):138-9.
Score: 0.439
-
Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion. Addiction. 2013 Dec; 108(12):2202-11.
Score: 0.430
-
Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials. Nicotine Tob Res. 2007 12; 9(12):1251-7.
Score: 0.288
-
Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob Res. 2007 Aug; 9(8):821-33.
Score: 0.281
-
Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome? Nicotine Tob Res. 2003 Dec; 5(6):935-42.
Score: 0.218
-
Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation. Pharmacogenomics J. 2012 Feb; 12(1):86-92.
Score: 0.086
-
A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation. Nicotine Tob Res. 2008 Jan; 10(1):231-40.
Score: 0.018